Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +22 vs. previous quarter
- 242
- 13F valueReported value at the end of Q2 2026
- $1.98B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SMMT, Q2 2026
No superinvestor reported holding SMMT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Summit Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 (view filing) | Jun 12 | Same day | Zanganeh MakyCo-Chief Executive Officer | PPurchase | +3.81M | $13.12 | +$50.0M | +0.7%573.9M after | Duplicate filing |
| Jun 12, 2026 (view filing) | Jun 12 | Same day | Duggan Robert WCo-Chief Executive Officer | PPurchase | +3.81M | $13.12 | +$50.0M | +0.7%573.9M after | |
| Jun 4, 2026 (view filing) | Jun 4 | Same day | Soni Manmeet SinghCOO and CFO | PPurchase | +50.0K | $14.45 | +$722.3K | +1.6%3.12M after | 2 lots |
| Jun 4, 2026 (view filing) | Jun 4 | Same day | Zanganeh MakyCo-Chief Executive Officer | PPurchase | +100.0K | $14.60 | +$1.46M | +0.4%25.8M after | Duplicate filing |
| Jun 4, 2026 (view filing) | Jun 4 | Same day | Duggan Robert WCo-Chief Executive Officer | PPurchase | +100.0K | $14.60 | +$1.46M | +0.4%25.8M after | |
| Oct 23, 2025 (view filing) | Oct 21 | 2 days | Xia YuDirector | PPurchase | +533.6K | $18.74 | +$10.0M | +1.7%32.1M after | |
| Oct 23, 2025 (view filing) | Oct 21 | 2 days | Zanganeh MakyCo-Chief Executive Officer | PPurchase | +26.7K | $18.74 | +$500.0K | +53.4%76.7K after | Duplicate filing |
| Oct 23, 2025 (view filing) | Oct 21 | 2 days | Duggan Robert WCo-Chief Executive Officer | PPurchase | +26.7K | $18.74 | +$500.0K | +53.4%76.7K after | |
| Sep 11, 2025 (view filing) | Sep 10-11 | 1 day | Zanganeh MakyCo-Chief Executive Officer | PPurchase | +338.4K | $17.69 | +$5.98M | +0.1%556.1M after | 2 lotsDuplicate filing |
| Sep 11, 2025 (view filing) | Sep 10-11 | 1 day | Duggan Robert WCo-Chief Executive Officer | PPurchase | +338.4K | $17.69 | +$5.98M | +0.1%556.1M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Summit Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 32,786,348 | $477.7M | 2.39% | −3,604,715−9.9% | Reduced |
| FMR LLC | 10,043,947 | $146.3M | 0.01% | −809,252−7.5% | Reduced |
| State Street Corp | 9,536,796 | $139.0M | 0.00% | +2,508,636+35.7% | Added |
| BlackRock, Inc. | 9,529,041 | $138.8M | 0.00% | −124,717−1.3% | Reduced |
| Vanguard Capital Management LLC | 5,734,484 | $83.6M | 0.00% | +22,682+0.4% | Added |
| UBS Group AG | 5,233,798 | $76.3M | 0.01% | +1,553,483+42.2% | Added |
| Vanguard Portfolio Management LLC | 5,042,190 | $73.5M | 0.00% | −191,062−3.7% | Reduced |
| Goldman Sachs Group Inc | 4,513,399 | $65.8M | 0.01% | +4,202,671+1,352.5% | Added |
| Price T Rowe Associates Inc | 3,893,820 | $56.7M | 0.01% | −4,384,039−53.0% | Reduced |
| Point72 Asset Management, L.P. | 3,697,803 | $53.9M | 0.08% | +2,913,617+371.5% | Added |